A therosclerosis leading to coronary artery, peripheral vascular, and cerebrovascular diseases is a chronic inflammatory disease that is the principal cause of death in the Western world. Early steps in atherogenesis include infiltration of the arterial wall by very-low-density lipoprotein and low-density lipoprotein, which activates endothelial cells and smooth muscle cells (SMCs) 1, 2 to upregulate leukocyte adhesion molecules and to secrete chemokines such as CCL2 and macrophage migration inhibitory factor (MIF), 3 in turn promoting the infiltration of leukocytes and lymphocytes into the subendothelial space, an event that begins the process of atheroma formation.
protease-activated receptors (PARs). Increased activity of tissue factor (TF), a 47-kDa cell membrane-bound glycoprotein that initiates the serine protease cascade, is seen in the neointima and underlying media of atherosclerotic plaques, [4] [5] [6] and TF is expressed by endothelial cells, 7 monocytes/macrophages, 8 and SMCs. 9 However, the cellular basis for how coagulation proteases act to promote atherogenesis has not been established.
We have previously defined the role that coagulation proteases play in the development of arteriosclerosis after endoluminal injury or allogeneic transplantation [10] [11] [12] [13] using a strain of transgenic mice expressing a membrane-tethered human TF pathway inhibitor (hTFPI) fusion protein on α-smooth muscle actin (SMA)-positive cells (α-TFPI-Tg mice). Here, we crossed α-TFPI-Tg mice with apolipoprotein E-deficient (ApoE −/− ) mice to generate a new strain (ApX4) to explore how inhibition of TF on SMCs influences the development of atherosclerosis.
Methods
An expanded methods section is available in the Materials section in the online-only Data Supplement.
Generation, Breeding, and Diets of Mice
α-TFPI-Tg mice 10 were crossed with ApoE −/− mice (The Jackson Laboratory, Bar Harbor, ME). First-generation offspring were crossed to obtain ApoE −/− mice expressing hTFPI. Founder mice were mated to generate the new strain (ApX4). Baseline phenotype was determined at 20 weeks after a normal chow diet (NCD). Some animals were fed a high-fat diet (HFD) for 6 or 12 weeks (35% fat, 1.25% cholesterol, and 0.5% cholic acid; Special Diet Services, Essex, UK), 14 starting at 6 weeks of age. Mice were housed in a temperature-controlled specific pathogen-free environment at 22°C to 24°C, and all procedures were approved by the UK Home Office.
Aortic Transplantation
A sleeve anastomosis technique was used for aortic transplantation. 12 Simply, a 5-mm segment of the infrarenal donor (MIF −/− mice, 15 C57BL/6 [Harlan Olac, Bicester, UK] mice, α-TFPI-Tg mice, or mice deficient in PAR-1 or -2 [The Jackson Laboratory]) aorta, flushed with 300 μL saline containing 50 U heparin, was transplanted into ApoE −/− recipients. Blood flow was confirmed by direct inspection after clamp removal.
Northern Blot Analysis
Total RNA was isolated from frozen tissues with the RNeasy RNA extraction kit (Qiagen, Valencia, CA) after tissue homogenization in TRIzol (Invitrogen, Carlsbad, CA) by use of a TissueLyser (Qiagen). RNA quality and quantity were determined by absorbance at 260 and 280 nm with the use of a NanoDrop 1000 spectrophotometer (Thermo Scientific). Northern blot was performed with a DIG Northern Starter kit (Roche Diagnostics, Mannheim, Germany), following the manufacturer's protocol. A mouse GAPDH cDNA fragment (Sigma, Dorset, UK) was used as control probe.
Serum and Plasma Assays
Human TFPI and mouse TFPI were detected with specific ELISA kits (Quantikine, R&D Systems, Abingdon, UK; and Antibodies-online Inc., Atlanta, GA, respectively). Plasma hTFPI activity was estimated with a chromogenic assay (Actichrome, American Diagnostica Inc, Stamford, CT). Total cholesterol, high-density lipoprotein, low-density lipoprotein, and triacylglycerol were determined with commercial kits (Cell Biolabs, Cambridge, UK; and Abcam, Cambridge, UK) according to the manufacturer's protocols. Plasma tumor necrosis factor-α, interferon-γ, and MIF were measured by ELISA according to the manufacturer's instructions (R&D Systems), as were thrombin antithrombin complexes (Dickinson, San Jose, CA) and D-dimers (Diagnostica Stago). 
Morphometric Analysis
Hearts were embedded in paraffin and sectioned through the aortic root before staining with elastin/van Gieson with the Accustain Elastin Stain kit (Sigma) for evaluation on an Olympus U-ULH microscope (Olympus Optical Co Ltd, Tokyo, Japan). Atheroma area is expressed as a percentage of total aortic root area that was determined with Image-Pro Plus TM software version 4.0 (Media Cybernetics, Silver Spring, MD). At least 3 random sections were examined from each of 10 mice. Longitudinally opened descending aortas were prepared as previously described 16 and evaluated for the extent of en face atherosclerosis after Oil Red O staining.
Immunohistochemistry
Sections were prepared and examined as previously described. 10, 12, 17 Briefly, tissues were snap-frozen in dry ice, embedded in optimum cutting temperature compound (VWR International, Dorset, UK), sectioned at 5-μm thickness, and fixed in methanol at -20°C. Frozen sections were immersed in 1% BSA-PBS for 30 minutes and then incubated overnight at 4°C with the antibodies defined in the online-only Data Supplement. Stained sections were mounted in Vectashield with DAPI (Vector Laboratories Inc, Burlingame, CA). Sections were directly captured and examined by a Leica DMIRBE confocal microscope equipped with Leica digital camera AG and a confocal laser scanning system with excitation lines at 405, 488, 543, and 560 nm at magnifications ×10/0.40CS and ×20/0.70IMM (Leica, Planapo, Wetzlar, Germany). Images were processed with associated Leica-TCS-NT software. All immunohistochemistry was performed at 22°C. The staining area was expressed as the ratio of the total lesion area, calculated with Image-Pro Plus TM, version 4.0. All quantification was performed by members of the team blinded to the identity of the sections. Average measurements were derived from at least 6 random sections from each sample.
Culture of Primary SMCs
Isolation and culture of SMCs have been described previously. 10 Briefly, mouse aortas with adventitia removed were washed with Dulbecco modified Eagle medium (Gibco BRL, Paisley, UK), minced, and digested in collagenase I (10 mg/mL), elastase (0.125 mg/mL), soybean trypsin inhibitor (0.25 mg/mL), bovine albumin (2.0 mg/mL), and HEPES (15 mmol/L; all from Sigma) at 37 o C for 45 minutes. After passage through a cell strainer and centrifugation, the resulting SMCs were cultured in Dulbecco modified Eagle medium supplemented with 10% FCS, 100 U/mL penicillin, and 100 μg/mL streptomycin until subconfluent at 37°C in a humidified 5% CO 2 incubator.
SMC-MIF Release Assay In Vitro and Factor IX, Factor X, and Thrombin Generation Assays
SMCs (1×10 6 cells per well in a 24-well plate) were serum starved for 24 hours before the addition of thrombin 50 nmol/L, factor Xa (FXa; 0-30 nmol/L; Enzyme Research Laboratories, Swansea, UK), increasing concentrations of PAR-1 and -2 agonists (Peptides International, Louisville, KY), p38 mitogen-activated protein kinase inhibitor SB203580 (10 μmol/L), p42/p44 inhibitor PD98059 (50 μmol/L), or nuclear factor-κB inhibitor SN502 (20 μmol/L; Merck Millipore, Hertfordshire, UK) for variable amounts of time. MIF was determined in supernatants.
In separate assays, washed SMCs (10 6 cells per well of a 96-well plate) were suspended in Dulbecco modified Eagle medium containing either 5 nmol/L FXa or 10 nmol/L factor VIIa (FVIIa) at 4°C. After 15 minutes, prepared 10 nmol/L factor Va (FVa) and 0.5 μmol/L prothrombin in HEPES-buffered saline buffer (Life Technologies, Grand Island, NY) were added for thrombin generation; factor IX, FX, FXI, or FXII at variable concentrations was added to assess factor IXa, FXa, FXIa, or FXIIa generation (Enzyme Research Laboratories). After defined times, aliquots of the reaction mixture were transferred into Tris-EDTA buffer with the chromogenic substrate Biophen CS-51(09) (Hyphen BioMed, Neuville sur Oise, France) for assessment of factor IXa or S-2238, S-2222, S-2366, or S-2302 for thrombin, FXa, FXIa, or FXIIa generation, respectively (Chromagenix, Milan, Italy). Absorbance at 405 nm was converted to concentrations with the use of purified standards control assays. To assess MIF production under these conditions, the assay was terminated after 20 minutes by washing the cells 5 times with PBS before reculturing in Dulbecco modified Eagle medium containing 2% FCS for 24 hours to obtain the supernatant used for MIF assessment. 
RNA Isolation and Quantitative Reverse Transcription-Polymerase Chain Reaction Analysis
Total RNA from SMCs was isolated with TRIzol reagent according to the manufacturer's instructions (RNeasy Plus Mini Kit, Qiagen, Hilden, Germany). First-strand cDNA was synthesized from 1 μg total RNA by use of the SuperScript III first-strand synthesis system (Invitrogen, Paisley, UK) as recommended by the manufacturer. Quantitative reverse transcription-polymerase chain reaction was performed with SYBR Green Mix (Thermo Scientific) in a quantitative reverse transcription-polymerase chain reaction system (AB7500, Applied Biosystems, Foster City, CA). Details of MIF and β-actin primers, thermal cycling conditions, and quantification of MIF RNA are given in the online-only Data Supplement. Fold increase in MIF was determined with the 2 −ΔΔCT (Livak) method.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software.
The Mann-Whitney test was used for comparison of 2 groups and the Kruskal-Wallis test for ≥3 groups. All data are presented as mean±SEM except in the Table, in which data are presented as mean±SD. A value of P<0.05 was considered significant. The pairwise P values are 2 sided, and because of the nature of the study, there are no adjustments for multiple comparisons.
Results

Baseline Characteristics of ApX4 mice
Transgene frequencies, assessed by polymerase chain reaction ( Figure 1A ), were as expected at each stage of breeding. ApX4 mice are viable and grow with normal physical characteristics at the same rates as both parental strains (Table) . Expression of hTFPI mRNA was found in aortas by Northern analysis ( Figure 1B ). Fusion protein expression was seen in the tunica media of large ( Figure 1C and 1D), medium, and small arteries; arterioles; and larger venules of all major tissues ( Figure I in the online-only Data Supplement) and in vitro-cultured aortic SMCs from ApX4 but not ApoE −/− mice ( Figure 1E ). In mice fed an NCD, there were no significant differences in circulating mouse or human TFPI or in human TFPI activity between ApoE −/− and ApX4 mice (Table) . After an HFD, levels of all 3 tended to increase in ApX4 or (ApX4×ApoE −/− ) hTFPI + littermates, although the differences remained statistically insignificant (Table) . There were no significant differences in the levels of circulating lipids in ApX4 compared with ApoE −/− mice or in hTFPI-positive or -negative littermates fed either type of diet (Table) . Expression of the hTFPI fusion protein had no significant impact on circulating thrombin antithrombin complexes or D-dimers (Table) , indicating no major perturbation of baseline systemic clotting or fibrinolysis.
Mild Atherosclerosis in ApX4 Mice Associated With Significant Reduction in Inflammation
ApX4 mice and (ApX4×ApoE −/− ) hTFPI + littermates developed significantly attenuated atherosclerosis after being fed an HFD for 6 or 12 weeks compared with ApoE −/− or negative littermate controls ( Figure 2 ). Obvious atheromatous lesions were also visible in ApoE −/− mice fed an NCD for 20 weeks, but they were almost undetectable in ApX4 mice ( Figure II in the onlineonly Data Supplement). Confocal examination of atheromatous lesions revealed that inflammatory cells expressing CD68, CD11b, or CD3 accounted for a significantly reduced proportion of lesional area in TFPI + compared with TFPI − mice ( Figure 3 and Figure II in the online-only Data Supplement). Analysis of circulating plasma tumor necrosis factor-α and interferon-γ showed that atheroma development in ApX4 mice (fed either type of diet) occurred in the context of significantly reduced systemic inflammation ( Figure 4A and 4B).
Specific Inhibition of MIF Expression by SMA + Cells in ApX4 Mice
Plasma levels of MIF in 20-week-old ApX4 mice fed an NCD were ≈25% those seen in age-matched ApoE −/− mice Figure 4C ). After an HFD, plasma MIF concentration was still significantly reduced compared with negative littermates or ApoE −/− mice ( Figure 4C ). By confocal analysis, cells expressing MIF occupied a significant proportion of typical atheromatous plaques in ApoE −/− mice ( Figure 4D and 4E ). In the α-SMA-rich lesions seen in mice fed an NCD, MIF was expressed predominantly by α-SMA + cells ( Figure 4E ). In contrast, there was little MIF staining within the small plaque areas seen in ApX4 mice, even though α-SMA + cells occupied the same proportional area ( Figure 4D and 4F). After an HFD, all SMA + cells in ApoE −/− mice coexpressed MIF, and these accounted for ≈25% of all MIF + cells within the plaques ( Figure 4E ), suggesting that expression by infiltrating leukocytes was responsible for the remaining 75%. The area occupied by cells expressing MIF in ApX4 mice was significantly reduced, consistent with reduced infiltration of leukocytes in these lesions ( Figure 4F ). Most important, although the proportional area occupied by SMA + cells in ApX4 mice fed an HFD for 12 weeks was similar to that seen in ApoE −/− (15±0.5% versus 27±1.8%; P<0.05), none of these cells coexpressed MIF ( Figure 4F ). These data indicate that hTFPI expression was associated with specific suppression of MIF expression by α-SMA + cells within atheromatous areas in ApX4 mice.
Additionally, in ApX4 mice fed an NCD, there was no MIF expression by SMCs within nonatheromatous areas of the vessel wall compared with ApoE −/− mice, in which all the media stained strongly for MIF ( Figure 4D ). These data indicate that MIF expression by SMCs was independent of plaque development. Similar findings in medial SMCs were seen in all the mice fed an HFD ( Figure III in the online-only Data Supplement). However, in these mice, it was obvious that CD31 + intimal cells distant from atheroma were MIF + in both hTFPI + and hTFPI − mice, indicating that endothelial cell expression of MIF was induced under these conditions and was not prevented by expression of the hTFPI on medial SMC.
Vessel Wall MIF Is Required for the Development of Atherosclerosis
To define the importance of vessel wall-derived MIF for atheroma development, we developed a congenic aortic transplantation model in ApoE −/− mice. Development of atheroma in the surrounding recipient aorta after an HFD was unaltered by the transplanted section ( Figure 5 ). Aortic transplants from mice completely deficient in MIF were resistant to atheroma development compared with MIF + littermates, which developed exaggerated atheroma ( Figure 5A , 5C, and 5H). Transplants from α-TFPI-Tg mice were also resistant, indicating that expression of hTFPI fusion protein on SMCs had the same functional impact as complete MIF deficiency. Aortic sections from PAR-1-and PAR-2-deficient mice were also protected compared with controls, suggesting that the effect of hTFPI might be to limit signaling through PARs on SMCs. Atheroma resistance was associated with absent MIF production by SMCs in the transplanted segments ( Figure IVA 
MIF Secretion by SMCs is TF and PAR Dependent.
To explore how hTFPI influenced MIF expression, SMCs from both ApoE −/− and ApX4 mice were first shown to be TF expressing ( Figure VA SMCs from ApoE −/− mice were incubated with FXa ( Figure 6A ), thrombin ( Figure 6D ), or prothrombin (with FXa, anionic phospholipid, and FVa to promote conversion to thrombin; Figure 6F ). MIF was induced under all these conditions. The effect of FXa was partially inhibited by an antagonist to either PAR-1 or PAR-2 ( Figure 6B ), whereas thrombin was inhibited by a PAR-1 but not a PAR-2 antagonist ( Figure 6E ). When FXa ( Figure 6C ) or thrombin ( Figure 6F and 6G) was generated in situ, MIF production was completely FVIIa dependent and completely inhibited by an anti-TF antibody. In contrast, cells from ApX4 mice made MIF after exposure to exogenously added thrombin ( Figure 6D) but not after addition of prothrombin, even when FXa and FVa or FVIIa, or FX and FVa were provided ( Figure 6F and 6G) , and ApX4 SMCs were resistant to the effects of exogenously added FXa ( Figure 6A) and FXa made in Figure 6C ). PAR-1-and PAR-2-dependent MIF secretion was transcriptionally induced and involved signaling through p42/p44 ERK and nuclear factor-κB pathways ( Figure VI in the online-only Data Supplement). PAR-1-induced MIF was also partly dependent on p38 kinase ( Figure VI in the online-only Data Supplement). All these data indicate that MIF production by SMCs in vitro is entirely TF and PAR dependent and, absent MIF production from ApX4, is consistent with the known anti-TF inhibitory effects of human TFPI. Finally, to demonstrate that the SMC-expressed hTFPI was inhibiting MIF expression in vivo, 6-week-old ApX4 mice were injected with an inhibitory anti-hTFPI antibody daily for 3 days. SMCs from these mice started to express MIF, like those from ApoE −/− mice ( Figure 7A ). This also significantly increased circulating MIF concentrations compared with animals injected with an isotype control to levels similar to those seen in ageand sex-matched ApoE −/− mice ( Figure 6H ), suggesting that, because hTFPI was expressed only on SMA + cells, plasma MIF levels were determined by MIF released from SMCs. Additionally, these effects were abolished by coadministration of active site-inhibited FVIIa (but not FXIIa) and mimicked by administration of a PAR-1 but not PAR-2 agonist ( Figures 6H  and 7A ), confirming the in vitro findings.
In ApoE −/− mice, injection of a PAR-1 antagonist, active site-inhibited FVIIa, or FXa and an inhibitory anti-TF antibody significantly reduced circulating MIF levels ( Figure 6H) , whereas a PAR-2 antagonist and active site-inhibited FXIIa had only a modest impact, indicating that systemic inhibition of TF had a similar impact on circulating MIF as expression of hTFPI on SMCs. Analysis of the arterial walls in these animals revealed changes in the expression of MIF within SMCs that mirrored those seen in plasma ( Figure 7B ).
All these data indicate that MIF expression by SMC in ApoE −/− mice is completely dependent on the activity of coexpressed TF and associated PAR-1 signaling by FXa and thrombin, inhibition of which by the hTFPI fusion protein in ApX4 mice is associated with a significant reduction in systemic MIF levels, reduced leukocyte recruitment, and marked inhibition of atherosclerosis.
Discussion
Previous studies have described how TFPI influences atherogenesis. For instance, mice deficient in TFPI show enhanced atherosclerosis. 18 However, there are 2 potential mechanisms operating in these mice, the first involving loss of the direct effects of TFPI on circulating lipids 19, 20 and the second involving loss of regulation of TF activity and resulting enhanced thrombin generation. To illustrate the first mechanism, transgenic mice overexpressing soluble TFPI were shown to be resistant to atherosclerosis as a result of a direct effect of soluble TFPI on very-low-density lipoprotein metabolism. 20 The importance of the second mechanism is illustrated when ApoE −/− mice are made deficient in HCII, a natural thrombin inhibitor, in that they develop severe atheroma. 21 Additionally, the direct thrombin inhibitor melagatran reduces lesion progression and maintains plaque stability in ApoE −/− mice. 22 In this study, using a new strain of transgenic mice expressing a membrane-tethered hTFPI fusion protein on SMA + cells, we provide an explanation of the molecular and cellular bases 
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Anti-TFPI PAR-1 antag PAR-2 antag FVIIai anti-TF FXIIai FXai physiological TFPIα and TFPIβ, mouse and human) are generated by alternative splicing and differ in their C-terminal structure and cellular localization. 23 TFPIα is a secreted protein with 3 tandem Kunitz-type domains (K1-K3) and a basic C-terminus, whereas TFPIβ has K1 and K2 domains and a glycosylphosphatidylinositol anchor membrane attachment. TFPIβ inhibits TF-mediated thrombin generation better than either TFPIα or a soluble truncated form of TFPI (TFPI-160) similar to TFPIβ, suggesting that cell surface association plays an important role in efficient inhibition of TF. 24 Conversely, K3 and the C-terminal region of TFPIα significantly enhance FXa inhibitory activity without having direct protease inhibitor activity themselves. 24 The fusion protein combines both cell-tethering and K3 effects and therefore acts as a highly efficient inhibitor of TF.
Our results indicate that vessel wall cells in ApX4 mice did not make MIF, which prevented inflammatory cell recruitment into the vessel wall. Resistance to atheroma formation was seen in mice fed either an NCD or an HFD but was more significant in mice fed chow in which MIF expression was almost exclusively restricted to α-SMA + cells. After a high-cholesterol diet, MIF was also obviously expressed by CD31 + endothelial cells Figure 6 continued. or ApX4 (squares) SMCs exposed to increasing concentrations of thrombin. E, ApoE −/− SMCs exposed to increasing concentrations of thrombin without inhibitors (circles) or with addition of 10 nmol/L PAR-1 (squares) or PAR-2 antagonist (triangles). and by infiltrating leukocytes within atheromatous plaques, which might explain why plasma MIF levels were higher in ApX4 mice after an HFD. Importantly, MIF was expressed by SMCs in areas of vessel wall remote from atheromatous lesions and was seen in mice before significant atheroma had developed, consistent with it being involved early in disease pathogenesis. 25 These results therefore indicate a crucial role for TF in the generation of MIF by SMCs in this model, a conclusion that is supported by all our in vitro and in vivo data. MIF was first described as a T-cell cytokine important for inhibiting macrophage migration in delayed-type hypersensitivity responses but is now known to be secreted by many different cell types and to have chemokine properties, attracting monocytes and T cells and binding, among other ligands, CXC chemokine receptors. 26 MIF expression within atheromatous plaques has been closely associated with progression and instability in human disease. 27 Moreover, deficiency of MIF is known to significantly impair atheroma development in low-density lipoprotein receptor-deficient mice, 28 and inhibition of MIF activity (using an anti-MIF antibody) prevents atherosclerosis in ApoE −/− mice. 29 In this context, it is MIF expression by cells in the vessel wall that is important, by initiating leukocyte recruitment. 25 In vitro experiments have suggested that MIF expression is induced in SMCs by hypoxia 30 and oxidized low-density lipoprotein. 31 Coagulation factors, including FXa and thrombin, are also known to induce MIF secretion by endothelial cells in vitro through activation of PAR-2 and PAR-1, respectively, 32 and have been shown to mediate secretion of other cytokines from SMCs. 33 Moreover, thrombin has been shown to induce MIF expression in diverse cell types. 34, 35 Our data confirm that FXa and thrombin induce MIF expression in SMCs and that SMCs expressing the tethered hTFPI fusion protein are resistant to both these factors (when thrombin has to be generated from prothrombin in situ by prothrombinase). The signaling pathways we have defined are similar to those described for coagulation protease-induced MIF expression in endothelial cells, 32, 36 thrombin signaling, 37 and MIF secretion in SMCs. 38 All these data are consistent with previous work from our group in which we demonstrated that TF and thrombin are necessary for in situ generation of local CXC chemokine gradients to initiate leukocyte recruitment after transplantation 39 and suggest that coagulation factors may perform a critical role of initiating leukocyte migration into or across the vessel wall.
Conclusions
Our data indicate that the proatherogenic stimuli that promote MIF expression by SMCs in vivo act via a TF-dependent mechanism and that inhibition of this can completely inhibit MIF secretion and the subsequent development of atherosclerosis. Like all mouse studies, our findings provide clues to the pathophysiology of human disease but cannot be directly extrapolated into humans. However, the definition of this novel mechanism, which involves no detectable perturbation of lipid metabolism, enhances our understanding of atheroma development, particularly the role that TF and coagulation proteases play, 40 and may lead to new translational strategies for intervention in human atherosclerosis. 
SUPPLEMENTAL MATERIAL
Methods
Generation, breeding and diets of mice
Immunohistochemistry
The following antibodies were used: Rabbit anti-mouse TF (American Diagnostic Inc.) anti-human TFPI (Enzyme Research Laboratories, Swansea, United Kingdom), MIF (Abcam, Cambridge, UK); rat anti-mouse CD68, CD11b (Serotec, Oxford, United Kingdom), CD31 or CD3 (BD Bioscience Pharmingen, Oxford, United Kingdom); mouse anti-SMA conjugated with Cy3 (Sigma). The following anti-IgG FITC or TRITC-conjugated antibodies were used: sheep anti-mouse, goat anti-rat and goat anti-rabbit (all Sigma).
qRT-PCR analysis.
Amplifications were performed using the thermal cycling conditions including enzyme activation at 95°C for 15 min, 40 cycles of denaturation at 95°C for 15 s, and annealing/extension at 55°C for 1 min. All samples were run in triplicate in three independent experiments. 평활근세포의 Tissue Factor가 염증세포의 침윤을 유도하여 죽상경화를 촉진시킨다
